CMS Says Mylan Paid Generics Rebate for Brand-Name EpiPen

Drug Industry Daily
A A
For years, Mylan has dodged paying the appropriate rebates for its epinephrine auto-injector EpiPen through a misclassification, the Centers for Medicare and Medicaid Services confirmed.

To View This Article:

Login

Subscribe To Drug Industry Daily